Werewolf Therapeutics (HOWL) Stock Price, Quote, News & History | Benzinga

Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History

HOWLNASDAQ

Trade with Public

Trade with Public

$0.9559

-0.0424-4.25%

Last update: Sep 3, 1:38 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$0.97

Close

-

Volume / Avg.

894.97K / 6.78M

Day Range

$0.94 - $1.02

52 Wk Range

0.27 - 2.38

Market Cap

$46.46M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

77

Short Interest

2.66%

Days to Cover

3.7

Recent Werewolf Therapeutics Inc News

Gold Moves Higher; US Composite PMI Surges In August

Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.

Avi Kapoor

Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings

US stocks rise, Dow gains over 350 points as markets open Friday; Materials sector up 2%, utilities down 0.3%. BJ's Wholesale Club beats earnings expectations and raises guidance.

Avi Kapoor

Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.

Vandana Singh

One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.

Surbhi Jain

Why Ross Stores Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Ross Stores beats estimates with Q2 financial results, shares jump 9.1%. Other gainers include RFAI, HOWL, SUGP, SDEV, ZKH, BTAI, SXTC, TREO, and ASST. Losers are JZ, DFNS, FLUX, and MMA.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-30.15M

Investing Cash Flow (TTM)

416.00K

Financing Cash Flow (TTM)

-26.77M

Free Cash Flow (TTM)

-30.15M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-56.50M

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$26.31M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.30

PB Ratio (TTM)

2.96

Earnings Yield % (TTM)

-73.46%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.34

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$21.99M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-$32.41M

Key Statistics

Open

$0.97

Close

-

Volume / Avg.

894.97K / 6.78M

Day Range

$0.94 - $1.02

52 Wk Range

0.27 - 2.38

Market Cap

$46.46M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

77

Short Interest

2.66%

Days to Cover

3.7

About

Sector

Health Care

Industry

Biotechnology

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PR...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Werewolf Therapeutics (HOWL) stock?

A

You can purchase shares of Werewolf Therapeutics (NASDAQ:HOWL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Werewolf Therapeutics (HOWL) competitors?

A

Other companies in Werewolf Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Werewolf Therapeutics (HOWL) stock?

A

Werewolf Therapeutics has a consensus price target of $6.50.

Q

What is the current price for Werewolf Therapeutics (HOWL)?

A

The stock price for Werewolf Therapeutics (NASDAQ: HOWL) is $0.9559 last updated September 3, 2026 at 1:38 PM EDT.

Q

Does Werewolf Therapeutics (HOWL) pay a dividend?

A

There are no upcoming dividends for Werewolf Therapeutics.

Q

When is Werewolf Therapeutics (NASDAQ:HOWL) reporting earnings?

A

Werewolf Therapeutics does not have any upcoming earnings scheduled.

Q

Is Werewolf Therapeutics (HOWL) going to split?

A

There is no upcoming split for Werewolf Therapeutics.

Q

What sector and industry does Werewolf Therapeutics (HOWL) operate in?

A

Werewolf Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.